The stock of Tscan Therapeutics Inc (TCRX) has seen a 5.34% increase in the past week, with a -32.41% drop in the past month, and a -38.53% decrease in the past quarter. The volatility ratio for the week is 6.74%, and the volatility levels for the past 30 days are at 10.15% for TCRX. The simple moving average for the last 20 days is -15.96% for TCRX stock, with a simple moving average of -51.19% for the last 200 days.
Is It Worth Investing in Tscan Therapeutics Inc (NASDAQ: TCRX) Right Now?
The 36-month beta value for TCRX is also noteworthy at 0.81. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TCRX is 43.51M, and at present, short sellers hold a 5.39% of that float. The average trading volume of TCRX on December 26, 2024 was 312.70K shares.
TCRX) stock’s latest price update
The stock price of Tscan Therapeutics Inc (NASDAQ: TCRX) has surged by 4.98 when compared to previous closing price of 2.91, but the company has seen a 5.34% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-26 that WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics’ common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions.
Analysts’ Opinion of TCRX
Many brokerage firms have already submitted their reports for TCRX stocks, with BTIG Research repeating the rating for TCRX by listing it as a “Buy.” The predicted price for TCRX in the upcoming period, according to BTIG Research is $12 based on the research report published on May 16, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see TCRX reach a price target of $11. The rating they have provided for TCRX stocks is “Buy” according to the report published on May 13th, 2024.
Wedbush gave a rating of “Outperform” to TCRX, setting the target price at $8 in the report published on June 22nd of the previous year.
TCRX Trading at -31.01% from the 50-Day Moving Average
After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.47% of loss for the given period.
Volatility was left at 10.15%, however, over the last 30 days, the volatility rate increased by 6.74%, as shares sank -33.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.30% lower at present.
During the last 5 trading sessions, TCRX rose by +6.21%, which changed the moving average for the period of 200-days by -54.44% in comparison to the 20-day moving average, which settled at $3.64. In addition, Tscan Therapeutics Inc saw -47.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TCRX starting from Lynx1 Capital Management LP, who purchase 100,000 shares at the price of $2.90 back on Dec 13 ’24. After this action, Lynx1 Capital Management LP now owns 5,357,347 shares of Tscan Therapeutics Inc, valued at $290,140 using the latest closing price.
Lynx1 Capital Management LP, the 10% Owner of Tscan Therapeutics Inc, purchase 31,800 shares at $3.01 during a trade that took place back on Dec 12 ’24, which means that Lynx1 Capital Management LP is holding 5,257,347 shares at $95,629 based on the most recent closing price.
Stock Fundamentals for TCRX
Current profitability levels for the company are sitting at:
- -12.76 for the present operating margin
- 0.61 for the gross margin
The net margin for Tscan Therapeutics Inc stands at -11.89. The total capital return value is set at -0.37. Equity return is now at value -55.92, with -34.81 for asset returns.
Based on Tscan Therapeutics Inc (TCRX), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -3.5. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -32.11.
Currently, EBITDA for the company is -80.1 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 12.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.56.
Conclusion
In summary, Tscan Therapeutics Inc (TCRX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
